WAY-267,464

From Wikipedia, the free encyclopedia
Jump to: navigation, search
WAY-267,464
WAY-267,464.png
Systematic (IUPAC) name
4-(3,5-dihydroxybenzyl)-N-(2-methyl-4-[(1-methyl-4,10-dihydropyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]benzyl)piperazine-1-carboxamide
Clinical data
Legal status Uncontrolled
Routes ?
Identifiers
CAS number 847375-16-0
ATC code None
PubChem CID 9938214
Chemical data
Formula C32H35N7O4 
Mol. mass 581.677 g/mol
 YesY (what is this?)  (verify)

WAY-267,464 is a drug which acts as a high affinity, potent, selective, and non-peptide agonist for the oxytocin receptor, with negligible affinity for the vasopressin receptors.[1][2] It has been shown to cross the blood-brain-barrier to a significantly greater extent than exogenously applied oxytocin, and in animal tests produces centrally-mediated oxytocinergic actions such as anxiolytic effects, but with no antidepressant effect evident.[3] It was developed by a team at Ferring.[4]

References[edit]

  1. ^ Rahman Z, Resnick L, Rosenzweig-Lipson SJ, Ring RH,"Methods of treatment using oxytocin receptor agonists", US patent application 2007/0117794, published 2007-05-24 , assigned to Wyeth Corp 
  2. ^ Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G (2008). "Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents". Progress in Brain Research 170: 473–512. doi:10.1016/S0079-6123(08)00437-8. PMID 18655903. 
  3. ^ Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, Grauer S, Pulicicchio C, Resnick L, Rahman Z, Sukoff Rizzo SJ, Luo B, Beyer CE, Logue SF, Marquis KL, Hughes ZA, Rosenzweig-Lipson S (July 2009). "Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist". Neuropharmacology 58 (1): 69–77. doi:10.1016/j.neuropharm.2009.07.016. PMID 19615387. 
  4. ^ European Patent 1512687 Piperazines as oxytocin agonists